Key result
Cotreatment with aliskiren and valsartan markedly reduced oxidative stress, glomerular collapse, and interstitial tissue expansion compared with aliskiren monotherapy in rats.
Why the study?
Does the combination of aliskiren and valsartan improve hypertensive nephropathy in L-NAME treated rats compared to monotherapy?
Does the combination of aliskiren and valsartan improve hypertensive nephropathy in L-NAME treated rats compared to monotherapy?
Combination therapy with aliskiren and valsartan provides additive renoprotective effects against structural injury in experimental hypertensive nephropathy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for additive renoprotection in hypertensive nephropathy models; leaves open clinical translation beyond monotherapy.
Hala Salah Abdel Kawy (2017) studied Hypertensive nephropathy. Aliskiren and valsartan combination vs. Aliskiren monotherapy and valsartan monotherapy was evaluated on Systolic blood pressure, proteinuria, oxidative stress, and structural renal injury. Cotreatment with aliskiren and valsartan markedly reduced oxidative stress, glomerular collapse, and interstitial tissue expansion compared with aliskiren monotherapy in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: